Mikhail Blagosklonny is a researcher in anti-aging and oncology with a reputation of providing significant results on developing effective medication in both. One of his major contributions is hyperfunction theory, a thesis that explained what is aging and what causes aging brilliantly which paved ways for further research in anti-aging. With the theory, Blagosklonny explained the aging as a continuation of growth nurtured by the signaling paths like Target of Rapamycin or TOR. This was contrary to the popular belief of aging as a functional decline of health due to molecular damage that could not be stopped. View his LinkedIn profile
Blagosklonny’s TOR-centric model earlier predicted that rapamycin and other rapalogs can be used in treating the aging and are also useful in preventing various diseases. With proper treatment regime, humans could expand the healthier lifespan in their later ages, according to Blagosklonny. This led to the introduction of Everolimus, a rapamycin analog in 2008, and now it is almost a decade with significant outputs which showed what Blagosklonny concluded was true and was based on thorough review and research. The critics of the theory now have a full praise for it due to the proven results over the years. Now, many research institutes and pharmaceutical firms are lined up on the research of “Youth Drug” which they believe the requirement of the future.
The hyperfunction theory also predicted the health impact of calorie-restriction-mimicking and the side-effects of rapalogs. For instance, rapamycin can increase the lipolysis which cause imitating fasting and conditions similar to starvation diabetes in few cases. The induced state of starvation blocks the complications of type II diabetes in reality. This paved the way for mTOR-centric model which predicts healthier span of life is not linked to insulin sensitivity, but can be promoted by the reduced mTOR pathway signaling. Interestingly, it was put forward by the critics of TOR-centric model, and considered as a major triumph for the model as mTOR was derived from the former. Blagosklonny concludes that with proper dosage and schedules of modalities and anti-aging drugs, people can make maximum extension of lifespan.
Mikhail Blagosklonny is currently working as a professor of Oncology at the prestigious Roswell Park Cancer Institute, New York, where he continues his research in anti-aging and oncology. He has more than a decade of clinical and research experience and worked with some reputed hospital and research institutes before joining Roswell Park. He started his career in 2002 by joining New York Medical College as the associate professor of medicine. By keeping further research in targeted medication of cancer, Blagosklonny joined Ordway Research Institute as a senior scientist and continued there until he joined Roswell Park in 2009.
Blagosklonny has published more than 300 reviews, research papers, book chapter, and more. He is also part of many science journals and working on their editorial boards in various roles. Blagosklonny earned his Master of Doctor in Internal Medicine from First Pavlov State Medical University located in St. Petersburg. He continued the research there and secured his Ph.D. in Cardiology and Experimental Medicine.
InnovaCare Inc. provides managed healthcare services in North America. Its headquarters are in Fort Lee, New Jersey. The company is committed to providing the public with affordable healthcare through Medicare Advantage, Provider Networks, and Medicaid Programs. InnovaCare Health provides these services with the help of cost-effective, technologically advanced and sustainable models. The success of InnovaCare in the provision of quality healthcare service is attributed to its strong leadership team, which is headed by Dr. Richard Shinto who is company’s president and chief executive officer, and Penelope Kokkinides who serves as the chief administrative officer.
Dr. Richard Shinto earned his degree in medicine from the renowned New York’s State University. He pursued his master’s degree in business administration from the University of Redlands. Rick Shinto graduated with a Bachelor of Science degree from the University of California. He began his medical career by serving as an intern in Southern California. He also worked as a pulmonologist. Previously, Rick Shinto served as a committed CEO of Aveta Inc. In addition, Shinto has held other high positions in different companies, including being the chief medical officer of NAMM California. Richard Shinto worked as the chief operating officer and chief medical officer for the celebrated Medical Pathways Management. He also served at Med Partners as a dedicated corporate vice president from 1996 to 1997. Rick Shinto has a broad experience in the competitive operational and clinical healthcare. He has also written numerous articles in matters of healthcare. Read more about her interview on Ideamensch.com
Penelope Kokkinides has enhanced administrative functions at InnovaCare Health. She holds a master’s degree in Public Health, which she earned from Columbia University. In addition, Penelope has a master’s degree from the New York University in Social Work. She pursued her undergraduate studies at Binghamton University. Before joining InnovaCare Health in 2015, Penelope Kokkinides worked for Aveta Inc. as the head of medical operations. She has broad experience in care management as well as Medicare programs and Medicaid. Penelope has also rendered her services as the corporate vice president in charge of disease and care management at AmeriChoice Company. She worked as a chief operating officer and executive vice president for Centerlight HealthCare. Penelope was also Touchstone Health’s chief operating officer.
In Puerto Rico, InnovaCare Inc. provides innovative healthcare services. Recently, the company added other experienced executives to its leadership team. These professionals are Jonathan Meyers who will serve as the chief actuary officer and Mike Sortino who shall be the company’s chief financial officer. According to hrmronline.com,
Through his extensive life research, he believes he can find a cure for cancer and aging using a drug known as Rapamycin. He was recently appointed as professor of oncology at the Roswell Park Cancer Institute, but this is not where he started. He began his journey at the First Pavlov State Medical University of St. Peterburg where he earned his Phd in experimental medicine, while also earning his M.D. in internal medicine and cardiology. Since then, his career and reputation have only grown. His interests lie in keeping safe of already healthy cells, while researching that of anti-aging drugs. Visit ResearchGate to keep up to date with Mikhail’s latest work.
His main point of view is essentially trying to utilize the drug Rapamycin (a common drug used to treat cancer) as an answer for allowing people to live longer and healthier lives. Blagosklonny is the creator of the aging hyperfunction theory. His research on tumor suppressors, drug resistance for normal cells selective protection, anticancer therapeutics, and mitosis, all lead him to believe that what he is doing is not only possible, but probable.
Mikhail Blagosklonny’s research has really turned out to be the pinnacle of his life. With over 300 research articles, one can trust that what he is saying is quite viable, and if not you can always look over his research for yourself. Essentially, his goal is to rid the world of cancer while figuring out the ways in which to stop the fast process of aging so that we may live, happy, healthy and long lives. View Mikhail’s profile on Google Scholar